RxDoctor Payments Data

Jean Muller, MD

Cardiovascular Disease · Compton, CANPI 1952305823

Payments from drug & device makers

$907in general payments, 2019–2025

Across 26 payments — averaging $34.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$222
  • Recor Medical Inc$149
  • Boston Scientific$149
  • Edwards Lifesciences$107
  • Novartis$62
  • Astellas Pharma US Inc$40
  • plus $179 from 8 others

What the payments were for

  • Food & beverage$907100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$907 in reported general payments places this provider in the 30th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$235,048
Medicare patients
1,013
Services billed
2,739

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban178$196,015
JardianceEmpagliflozin101$95,789
Repatha SureclickEvolocumab66$60,658
EntrestoSacubitril/Valsartan53$55,001
XareltoRivaroxaban45$46,424
MultaqDronedarone Hcl15$35,892
Praluent PenAlirocumab28$17,186
Amiodarone Hcl104$4,721
Ezetimibe99$4,615
Flecainide Acetate30$3,810
Metoprolol Succinate271$3,618
Atorvastatin Calcium254$2,652
Spironolactone245$2,579
Losartan Potassium183$2,571
Valsartan63$2,461

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$62$55,00153 claims
Johnson & JohnsonXarelto$27$46,42445 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Compton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →